The proposed research aims to solve important analytical problems arising in almost every clinical study, in which the endpoint is the time to a certain clinical or biological event (e.g., the time to death, AIDS, HIV-RNA failure, etc.). In particular, this project proposes to address the following specific aims: 1. To develop model and variable selection techniques based on aggregate, clinically-meaningful prediction error in regression models for binary, continuous, and censored event outcomes; 2. To study methods for assessing the added value of expensive or invasive markers for predicting outcome or diagnosing disease in HIV and other infectious disease studies using the prediction criteria developed and studied in Aim 1; 3. To develop new sensitivity analysis tools for survival, analysis in the presence of informative censoring; and 4. To develop efficient combinations of a class of estimates for survival models for non-proportional hazards semi-parametric models with censored failure time data. Relevance To Public Health Important progress has been made in the last 15 years in HIV research, resulting in an increase in the treatment options for HIV-infected individuals. The increasingly detailed biologic measurements in HIV,such as genetic mutations in the virus or information in a patient's genome, now provide the opportunity not only for estimating population effects, but also for developing models for predicting individual patient outcomes, including potential toxic side effects of therapy, biologic response, or the time to clinical or biologic failure. The results of this research are expected to assist clinicians in providing better care and case management for patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI052817-06
Application #
7348296
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Gezmu, Misrak
Project Start
2002-09-30
Project End
2009-08-14
Budget Start
2008-02-01
Budget End
2009-08-14
Support Year
6
Fiscal Year
2008
Total Cost
$250,967
Indirect Cost
Name
Harvard University
Department
Biostatistics & Other Math Sci
Type
Schools of Public Health
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02115
Claggett, Brian; Tian, Lu; Castagno, Davide et al. (2015) Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints. Biostatistics 16:60-72
Shen, Yuanyuan; Liao, Katherine P; Cai, Tianxi (2015) Sparse kernel machine regression for ordinal outcomes. Biometrics 71:63-70
Parast, Layla; Tian, Lu; Cai, Tianxi (2014) Landmark Estimation of Survival and Treatment Effect in a Randomized Clinical Trial. J Am Stat Assoc 109:384-394
Tian, Lu; Zhao, Lihui; Wei, L J (2014) Predicting the restricted mean event time with the subject's baseline covariates in survival analysis. Biostatistics 15:222-33
Uno, Hajime; Claggett, Brian; Tian, Lu et al. (2014) Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol 32:2380-5
Matsouaka, Roland A; Li, Junlong; Cai, Tianxi (2014) Evaluating marker-guided treatment selection strategies. Biometrics 70:489-499
Zhao, Lihui; Tian, Lu; Cai, Tianxi et al. (2013) EFFECTIVELY SELECTING A TARGET POPULATION FOR A FUTURE COMPARATIVE STUDY. J Am Stat Assoc 108:527-539
Zhao, Lihui; Hu, X Joan (2013) Estimation with Right-Censored Observations Under A Semi-Markov Model. Can J Stat 41:237-256
Zhou, Qian M; Zheng, Yingye; Cai, Tianxi (2013) Subgroup specific incremental value of new markers for risk prediction. Lifetime Data Anal 19:142-69
Parast, Layla; Cai, Tianxi (2013) Landmark risk prediction of residual life for breast cancer survival. Stat Med 32:3459-71

Showing the most recent 10 out of 25 publications